Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,600 | 2020-04-26 00:00:00 UTC | Wall St Week Ahead-Spotlight falls on 'dividend aristocrats' after market tumult | ABBV | https://www.nasdaq.com/articles/wall-st-week-ahead-spotlight-falls-on-dividend-aristocrats-after-market-tumult-2020-04-26 | null | null | By Lewis Krauskopf
NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income.
Th... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the corona... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chev... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the corona... |
24,601 | 2020-04-24 00:00:00 UTC | Wall St Week Ahead-Spotlight falls on 'dividend aristocrats' after market tumult | ABBV | https://www.nasdaq.com/articles/wall-st-week-ahead-spotlight-falls-on-dividend-aristocrats-after-market-tumult-2020-04-24 | null | null | By Lewis Krauskopf
NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the coronavirus outbreak, complicating the stock selection process for money managers eager to buttress their portfolios with a steady stream of income.
Th... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the corona... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The past week's plunge in oil prices has potentially accelerated that process, raising concerns about the rock-steady dividends of companies such as Exxon Mobil XOM.N and Chev... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. The S&P 500 dividend aristocrats index .SPDAUDT, which tracks companies that have increased dividends annually for the past 25 years and includes Exxon and Chevron, has fallen... | AbbVie ABBV.N, 3M Co MMM.N and Aflac AFL.N, which are in the dividend aristocrats index, are also due to report first-quarter results next week. By Lewis Krauskopf NEW YORK, April 24 (Reuters) - Companies across a range of industries are slashing or suspending dividends to cope with the economic fallout from the corona... |
24,602 | 2020-04-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Medigus, Pluristem Therapeutics, Whiting Petroleum | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-medigus-pluristem-therapeutics-whiting-petroleum-2020-04-24 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The Dow Jones was under pressure on Friday, hurt by declines in Boeing and Intel, with investors staying cautious about an economic recovery as some states ... | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percenta... | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percenta... | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percenta... | The top three S&P 500 .PG.INX percentage gainers: ** Sysco Corp , up 7.5% ** Tractor Supply Co , up 6.1% ** Freeport-McMoRan Inc , up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 10.6% ** Boeing Co , down 6.2% ** Simon Property Group , down 5.9% The top three NYSE .PG.N percenta... |
24,603 | 2020-04-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Whiting Petroleum, Medigus, Pluristem Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-whiting-petroleum-medigus-pluristem-therapeutics-2020-04-24 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 edged higher in choppy trading on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, but declines in Int... | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainer... | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainer... | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainer... | The top three S&P 500 .PG.INX percentage gainers: ** Freeport-McMoRan Inc , up 8.8% ** Invesco Ltd , up 6.2% ** Sysco Corp , up 5.3% The top three S&P 500 .PL.INX percentage losers: ** Helmerich & Payne Inc , down 5.3% ** Simon Property Group Inc , down 5.3% ** Boeing Co , down 4.9% The top NYSE .PG.N percentage gainer... |
24,604 | 2020-04-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Pluristem Therapeutics, J.C. Penney, Medigus | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-pluristem-therapeutics-j.c.-penney-medigus-2020-04-24 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock markets were set to gain at the open on Friday as some states prepared to relax curbs imposed to contain the coronavirus outbreak, with a surpris... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS International Inc , up 58.3% ** Denbury Resources Inc , up 51.8% ** Valaris Plc , up 43.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Brightsphere Investment Group Inc , down 38% ** KT Corp , down 20% ** J.C. Penney Company Inc , down 14.... |
24,605 | 2020-04-23 00:00:00 UTC | These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys? | ABBV | https://www.nasdaq.com/articles/these-3-biotechs-had-successful-ipos-during-the-coronavirus-crisis.-are-they-buys-2020-04 | null | null | An initial public offering (IPO) has a special allure: It draws in speculative investors eager to see stocks soar in the initial days of trading. In weak markets, only the strongest candidates pull off an IPO. Lesser-quality companies delay or withdraw the offering, typically citing market conditions.
Since the beginni... | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Backed by prominent healthcare investors including New Enterprise Associates, Orbimed, the venture arm of Pfizer, and RA Capital, Imara faces competition from Global Blood Therapeutics (NASDAQ: GBT), which gained... | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Backed by prominent healthcare investors including New Enterprise Associates, Orbimed, the venture arm of Pfizer, and RA Capital, Imara faces competition from Global Blood Therapeutics (NASDAQ: GBT), which gained... | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. Imara plans to start a Phase 2b clinical trial of IMR-687 in the first half of 2020 for sickle cell disease, a genetic condition that causes red blood cells to become misshapen, leading to aggregation of those ce... | Another drug from Zentalis, Zn-d5 ,has Abbvie and Roche's leukemia treatment, Venclexta, in its crosshairs. IMR-687 provides an oral treatment for the 100,000 U.S. patients and 134,000 European patients living with the disease. MF is rare, with fewer than 18,500 patients in the U.S., but 38% of patients are dependent o... |
24,606 | 2020-04-23 00:00:00 UTC | Better Buy: AbbVie vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-gilead-sciences-2020-04-23 | null | null | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growth potential and reduce its reliance on the world's current top-selling drug, Humira. Meanwhile, Gilead's investigational corona... | AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growth potential and reduce its reliance on the world's current top-selling drug, Humira. AbbVie and Allergan have met conditions required for the transaction to move forward in Europe and are now awaiting approval from the Federal Trad... | The case for AbbVie Blockbuster anti-inflammatory drug Humira, with $19 billion in annual sales, accounts for 60% of AbbVie's annual revenue. And the addition of Allergan's portfolio lifts AbbVie's plans for annual growth, with sales of more than $30 billion in 2020 -- excluding Humira -- and expectations for a high si... | The case for AbbVie Blockbuster anti-inflammatory drug Humira, with $19 billion in annual sales, accounts for 60% of AbbVie's annual revenue. I think AbbVie and Gilead are both good investments, but if I had to choose just one to buy right now, I would go with AbbVie. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GI... | I think AbbVie and Gilead are both good investments, but if I had to choose just one to buy right now, I would go with AbbVie. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growt... |
24,607 | 2020-04-22 00:00:00 UTC | Johnson & Johnson and AbbVie Earn a New FDA Approval for Imbruvica | ABBV | https://www.nasdaq.com/articles/johnson-johnson-and-abbvie-earn-a-new-fda-approval-for-imbruvica-2020-04-22 | null | null | Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. On Tuesday, the Food and Drug Administration approved the combination of Imbruvica and Rituximab as a treatment for patients with previously untreated chronic lymphocytic leukemia ... | With sales of Humira -- by far AbbVie's biggest moneymaker -- losing steam in Europe due to competition from biosimilars, the pharma giant has high hopes for Imbruvica. Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & J... | Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction... | Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-focused biotech company that was acquired by AbbVie back in 2015 in a cash and stock transaction... | Johnson & Johnson and AbbVie equally share the profits (and losses) from the sale of Imbruvica. Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. Johnson & Johnson originally co-developed Imbruvica with Pharmacyclics, an oncology-... |
24,608 | 2020-04-22 00:00:00 UTC | 3 Great Reasons to Buy Gilead Sciences Stock | ABBV | https://www.nasdaq.com/articles/3-great-reasons-to-buy-gilead-sciences-stock-2020-04-22 | null | null | Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental drug remdesivir to be successful in clinical studies targeting COVID-19. There have been some early hints at positive results, but it's too soon to know for sure how safe and effective remdesivir will actually be in treating the novel corona... | Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental dr... | Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental dr... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. Like many people, I'm rooting for Gilead Sciences' (NASDAQ: GILD) experimental dr... | Another good reason to like the stock is the duopoly that it shares with AbbVie in the hepatitis C virus (HCV) market. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Gilead Sciences. GS-6207 could be the future of Gilead's HIV franchise and potentially even top Bi... |
24,609 | 2020-04-22 00:00:00 UTC | 2 Best Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/2-best-dividend-stocks-to-buy-now-2020-04-22 | null | null | What will happen after the COVID-19 pandemic from an economic standpoint is anyone's guess. The oil and gas industry, airlines, cruise ships, sit-in restaurants, and even the financial services space are all facing an uphill battle at the moment.
Numerous household names may, in fact, vanish when everything is said and... | Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. AbbVie: A dirt cheap Dividend Aristocrat AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have ... | AbbVie: A dirt cheap Dividend Aristocrat AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have increased their dividends for 25 consecutive years or more. Despite AbbVie's proven commitment to paying a top-notch dividend, investors haven't exactly flocked to this name as of l... | Armed with this insight, investors should take a look at AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) -- both are perhaps the two best dividend-paying pharma stocks to buy right now. AbbVie: A dirt cheap Dividend Aristocrat AbbVie is a Dividend Aristocrat, meaning that it belongs to a select group of companies that have ... | Despite AbbVie's proven commitment to paying a top-notch dividend, investors haven't exactly flocked to this name as of late. Keeping with this theme, AbbVie's shares are trading at less than nine times projected earnings and are down by almost 18% at the time of this writing from their 52-week high. Armed with this in... |
24,610 | 2020-04-21 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2020-04-21 | null | null | Dividend stocks can be a great source of income, especially during challenging times like these. They can help provide stability for your portfolio and minimize your losses during a market crash as well. Stable dividend stocks are in short supply lately, but the three stocks listed below offer investors a good mix of v... | The acquisition of Allergan should strengthen AbbVie over the long term, and it could pave the way for more dividend increases in the future, making it an even better buy for income investors today. AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of... | AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. AbbVie as a whole saw its top line rise by just 1.6% last year. The move will add some high-profile drugs into AbbVie's portfolio that could hel... | AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's disease. AbbVie as a whole saw its top line rise by just 1.6% last year. The move will add some high-profile drugs into AbbVie's portfolio that could hel... | While UPS doesn't have the impressive track record for dividend growth that AbbVie has, it's been increasing its payouts on a regular basis since 2010. AbbVie AbbVie (NYSE: ABBV) is a top drug manufacturer, and its Humira drug is critical for patients with various types of arthritis as well as people who have Crohn's d... |
24,611 | 2020-04-21 00:00:00 UTC | 8 Safe High-Yield Dividend Stocks Offering 5% or More | ABBV | https://www.nasdaq.com/articles/8-safe-high-yield-dividend-stocks-offering-5-or-more-2020-04-21 | null | null | Steep market declines in 2020 have not only been brutal on returns; they've also presented income investors with a conundrum. The market is suddenly flooded with a glut of high-yield dividend stocks, but dividends in general are less safe than they've been in more than a decade.
The S&P 500 has quickly risen from a yie... | SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (... | SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (... | As a standalone entity, AbbVie has generated seven years of dividend hikes - including a 35% boost announced in February - and an 18% annual dividend growth rate over the past half-decade ABBV has long been among the market's safest high-yield dividend stocks. SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Marke... | SEE ALSO: 20 Best Stocks to Buy Now for the Next Bull Market AbbVie Market value: $124.0 billion Dividend yield: 5.6% Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for autoimmune disorders, cancers, viruses and neurological conditions. Other important AbbVie drugs include Imbruvica and Venclexta (... |
24,612 | 2020-04-20 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and the Dow Jones headed lower on Monday following a strong two-week rally as oil prices crashed and investors grew cautious at the start of a w... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .... |
24,613 | 2020-04-20 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-DuPont, Occidental Petroleum, Safe-T Group | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dupont-occidental-petroleum-safe-t-group-2020-04-20 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
A slide in energy stocks weighed on Wall Street on Monday as crude prices crashed at the start of a week packed with quarterly earnings reports and economic... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three ... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three ... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three ... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three ... |
24,614 | 2020-04-20 00:00:00 UTC | Noteworthy ETF Inflows: VTV, HON, ABBV, GE | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vtv-hon-abbv-ge-2020-04-20 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $1.2 billion dollar inflow -- that's a 2.5% increase week over week in outstanding units (from 471,419,044 to 483,182,7... | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the o... | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the o... | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cove... | Among the largest underlying components of VTV, in trading today Honeywell International Inc (Symbol: HON) is off about 1.7%, AbbVie Inc (Symbol: ABBV) is off about 0.4%, and General Electric Co (Symbol: GE) is lower by about 4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cove... |
24,615 | 2020-04-20 00:00:00 UTC | EXCLUSIVE-In Russia, a black market for HIV drug to try on coronavirus | ABBV | https://www.nasdaq.com/articles/exclusive-in-russia-a-black-market-for-hiv-drug-to-try-on-coronavirus-2020-04-20 | null | null | By Polina Ivanova
MOSCOW, April 20 (Reuters) - A black market has developed in Russia for an antiviral HIV drug explored as a possible treatment for COVID-19, the respiratory disease caused by the new coronavirus, according to sellers, HIV activists and the head of the drug's main Russian producer.
More than 20 trials ... | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. The director of H-Clinic in St. Petersburg, which specialises in infectious diseases and keeps a stock to cover those needs, said his ph... | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. Russia's Health Ministry recommended it as a possible treatment for COVID-19 at the end of January after reports from China that it was ... | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. By Polina Ivanova MOSCOW, April 20 (Reuters) - A black market has developed in Russia for an antiviral HIV drug explored as a possible t... | Produced in Russia by R-Pharm under a deal with the U.S. drug maker and patent-holder AbbVie Inc ABBV.N, Kaletra is supplied in smaller quantities to some pharmacies and AIDS clinics. One HIV activist in central Russia said speculators were trying to buy Kaletra from HIV patients, for 3,000 roubles a box. "Messages and... |
24,616 | 2020-04-19 00:00:00 UTC | 3 Stocks to Supplement Your Social Security Income | ABBV | https://www.nasdaq.com/articles/3-stocks-to-supplement-your-social-security-income-2020-04-19 | null | null | Don't expect Social Security will be enough to fund your retirement. The federal program was intended to provide only around 40% of retirees' income. You'll need to make up the rest on your own.
One of the best alternatives to help you accomplish this goal is to invest in dividend stocks. In particular, you'll want to ... | The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. And since being spun off from Abbott in 2013, AbbVie has nearly tripled its div... | AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend increases including the time that AbbVie was part of Abbott Labs (NYSE: ABT). And since being spun off from Abbott in 2013, AbbVie has nearly tripled its div... | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive ... | The primary risk with AbbVie is that it's heavily dependent on sales of one drug, Humira, which generated nearly 58% of the company's total revenue in 2019. AbbVie AbbVie (NYSE: ABBV) offers a dividend yield of close to 5.8%. The big drugmaker's track record looks very impressive, with 47 consecutive years of dividend ... |
24,617 | 2020-04-17 00:00:00 UTC | Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys | ABBV | https://www.nasdaq.com/articles/dont-waste-your-money-on-penny-stocks-these-2-stocks-are-better-buys-2020-04-17 | null | null | The uncertainty that has gripped stock markets around the world makes at least one thing clear: This is no time to buy penny stocks. There never was a good time, really. Most companies that trade as penny stocks are outright scams, with many having no actual operations at all. More importantly, owning those types of as... | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. For that reason, the Food and Drug Administration requires clinical trials of biosim... | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. The quick start helped the business generate full-year 2019 operating income of $107... | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. Here's why investors might want to take a closer look at Coherus BioSciences (NASDAQ... | The company is developing biosimilars for both Lucentis and Eylea, each of which is used to treat wet age-related macular degeneration (wet AMD), as well as a biosimilar to AbbVie's blockbuster Humira for treating autoimmune disorders. The uncertainty that has gripped stock markets around the world makes at least one t... |
24,618 | 2020-04-16 00:00:00 UTC | Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors | ABBV | https://www.nasdaq.com/articles/gilead-sciences-remdesivir-data-release-brings-much-needed-relief-for-patients-and | null | null | For years, Gilead Sciences' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four... | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. For years, Gilead Sciences' (NAS... | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. Within a subgroup of patients re... | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. While shares do boast an impress... | Considering other potential therapies such as AbbVie's (NYSE: ABBV) Kaletra stumbled in one investigation and how hydroxychloroquine was revealed to possess serious adverse events such as sudden death, remdesivir has become the leading candidate in potentially combating the coronavirus. Investors should consider adding... |
24,619 | 2020-04-16 00:00:00 UTC | How Safe Are AbbVie Stock and Its Dividend? | ABBV | https://www.nasdaq.com/articles/how-safe-are-abbvie-stock-and-its-dividend-2020-04-16 | null | null | Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction... | AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering... | AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the ... | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first... | But AbbVie has more going for it. In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. |
24,620 | 2020-04-15 00:00:00 UTC | 4 Dirt-Cheap Dividend Stocks to Buy as the Coronavirus Pandemic Continues | ABBV | https://www.nasdaq.com/articles/4-dirt-cheap-dividend-stocks-to-buy-as-the-coronavirus-pandemic-continues-2020-04-15 | null | null | If you're looking for safe, steady investments in these turbulent times, there's a surprising number of good choices. With many companies now trading at steep discounts due to the downturn fueled by the COVID-19 pandemic, now's an excellent time to grow your portfolio with high-quality, dividend-paying stocks.
One of t... | The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. AbbVie When it comes to pharmaceutical companies boasting sky-high dividend... | AbbVie When it comes to pharmaceutical companies boasting sky-high dividends, look no further than AbbVie (NYSE: ABBV). The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the wor... | The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. Although AbbVie's overall revenue growth is slower than that of some of the... | The stock currently offers a 5.9% dividend yield for investors, with a P/S ratio of 3.6 and trailing P/E multiple of 15.. AbbVie holds the distinction of owning one of the top-selling drugs in the world, an inflammatory treatment called Humira. Although AbbVie's overall revenue growth is slower than that of some of the... |
24,621 | 2020-04-13 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Allergan and Abbott Laboratories | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-allergan-and-abbott-laboratories-2020-04-13 | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will p... | As a percentage of ABBV's recent stock price of $81.08, this dividend works out to approximately 1.46%, so look for shares of AbbVie Inc to trade 1.46% lower — all else being equal — when ABBV shares open for trading on 4/14/20. If they do continue, the current estimated yields on annualized basis would be 5.82% for Ab... | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will p... | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will p... | As a percentage of ABBV's recent stock price of $81.08, this dividend works out to approximately 1.46%, so look for shares of AbbVie Inc to trade 1.46% lower — all else being equal — when ABBV shares open for trading on 4/14/20. If they do continue, the current estimated yields on annualized basis would be 5.82% for Ab... |
24,622 | 2020-04-13 00:00:00 UTC | Reasons for hope: the drugs, tests and tactics that may conquer coronavirus | ABBV | https://www.nasdaq.com/articles/reasons-for-hope%3A-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-2020-04-13 | null | null | By Christine Soares
April 13 (Reuters) - With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the ... | Even moderately effective therapies or combinations could dramatically reduce the crushing demand on hospitals and intensive care units, changing the nature of the risk the new pathogen represents to populations and healthcare systems. A single-center phase 1 trial with 108 subjects aged 18-60 in Wuhan, Hubei, China, s... | Data on arthritis drug to treat coronavirus could come within weeks, according to Regeneron executive Link: https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/data-on-arthritis-drug-to-treat-coronavirus-could-come-within-weeks-regeneron-executive-idUSKCN21R2WN Exclusive: Sanofi can produce millions ... | Gilead starts two late-stage studies to test drug for coronavirus Link: https://www.reuters.com/article/us-health-china-gilead-sciences/gilead-starts-two-late-stage-studies-to-test-drug-for-coronavirus-idUSKCN20K38J Investors await data on coronavirus drugs as market rally builds Link: https://www.reuters.com/article/u... | In early April, a trial in the Netherlands launched to test IFX-1 in patients with severe COVID-19 pneumonia, with preliminary results expected in late October 2020. Novavax to start human trial for novel coronavirus vaccine Link: https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-to-start-human-tria... |
24,623 | 2020-04-12 00:00:00 UTC | Is Galapagos Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-galapagos-stock-a-buy-2020-04-12 | null | null | After its stock reached all-time highs in February, Galapagos (NASDAQ: GLPG) saw those gains disappear. Don't fret, though. The stock price is down less than 1% year to date -- a decrease many investors, and companies, can only dream of in the current environment.
Is Galapagos's lack of price decline a signal of qualit... | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. According to a January 2020 report to Congress from the U.S. Government Accounta... | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. Gilead paid $3.95 billion and made a $1.1 billion equity investment into Galapag... | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. The company's lead drug, filgotinib, awaits regulatory approval in the U.S., Eur... | AbbVie (NYSE: ABBV) received FDA approval last August for Rinvoq, its once-daily oral treatment for patients with moderate to severely active RA who have an inadequate or intolerant response to an existing RA treatment called methotrexate. Filgotinib approval decision The biggest catalyst for Galapagos will be the pote... |
24,624 | 2020-04-11 00:00:00 UTC | 3 Top Pharma Stocks to Buy in April | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-april-2020-04-11 | null | null | In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue ... | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the... | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the... | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. |
24,625 | 2020-04-11 00:00:00 UTC | 3 Top Pharma Stocks to Buy in April | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-april-2020-04-11-0 | null | null | In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue ... | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the... | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the... | AbbVie There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future. Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. |
24,626 | 2020-04-08 00:00:00 UTC | Better Coronavirus Stock: Emergent BioSolutions vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-coronavirus-stock%3A-emergent-biosolutions-vs.-gilead-sciences-2020-04-08 | null | null | To be sure, no drug has yet been proven to be effective in treating novel coronavirus disease COVID-19. Any claims that you might read online about one drug or another being a silver bullet for the disease are premature at best. However, what is true right now is that several companies are developing therapies that hol... | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. These include a pediatric cholera vaccine that's currently in late-stage testing and th... | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. Two of the players at the forefront of these efforts are Emergent BioSolutions (NYSE: E... | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. The case for Gilead Sciences Gilead Sciences just might have the most promising COVID-1... | And the company's hepatitis C virus (HCV) franchise enjoys a virtual duopoly with AbbVie (NYSE: ABBV), although sales have fallen in large part because there are fewer new patients now that so many patients with HCV have been cured. To be sure, no drug has yet been proven to be effective in treating novel coronavirus d... |
24,627 | 2020-04-07 00:00:00 UTC | In a first, China knocks U.S. from top spot in global patent race | ABBV | https://www.nasdaq.com/articles/in-a-first-china-knocks-u.s.-from-top-spot-in-global-patent-race-2020-04-07 | null | null | By Stephanie Nebehay
GENEVA, April 7 (Reuters) - China was the biggest source of applications for international patents in the world last year, pushing the United States out of the top spot it has held since the global system was set up more than 40 years ago, the U.N. patent agency said on Tuesday.
The World Intellect... | According to the WIPO data, China's Huawei Technologies HWT.UL, the world's biggest maker of telecoms equipment, was the top corporate patent filer for the third consecutive year. The United States has called on countries to ban Huawei equipment from new mobile phone networks, arguing that its technology could be used ... | By Stephanie Nebehay GENEVA, April 7 (Reuters) - China was the biggest source of applications for international patents in the world last year, pushing the United States out of the top spot it has held since the global system was set up more than 40 years ago, the U.N. patent agency said on Tuesday. The United States h... | By Stephanie Nebehay GENEVA, April 7 (Reuters) - China was the biggest source of applications for international patents in the world last year, pushing the United States out of the top spot it has held since the global system was set up more than 40 years ago, the U.N. patent agency said on Tuesday. The World Intellect... | The World Intellectual Property Organization, which oversees a system for countries to share recognition of patents, said 58,990 applications were filed from China last year, beating out the United States which filed 57,840. WIPO's head, Francis Gurry, told a news conference China's success was "down to a very delibera... |
24,628 | 2020-04-07 00:00:00 UTC | U.N. agency says coronavirus emergency could trump some patent rights | ABBV | https://www.nasdaq.com/articles/u.n.-agency-says-coronavirus-emergency-could-trump-some-patent-rights-2020-04-07 | null | null | By Stephanie Nebehay
GENEVA, April 7 (Reuters) - Discussions are under way on enabling wider access to some patented drugs and medical supplies during the coronavirus pandemic, the head of the U.N.'s intellectual property agency said on Tuesday.
Francis Gurry, director-general of the World Intellectual Property Organiz... | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs ... | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs ... | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs ... | Israel last month invoked an emergency patent-suspension clause, allowing it to import a generic version of anti-viral drug Kaletra produced by AbbVie Inc ABBV.N Gurry said tech start-ups and creative industries including musicians and actors should be covered in compensation packages for the crisis which has hit jobs ... |
24,629 | 2020-04-07 00:00:00 UTC | Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing | ABBV | https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07 | null | null | Help is on the way.
In the midst of a societal upheaval resulting from the novel coronavirus and the disease that it causes, COVID-19, there are many efforts in progress to find solutions to slow the spread of the disease and treat those who already have it. These efforts include those from governments, nonprofit organ... | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead S... | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead S... | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead S... | AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead S... |
24,630 | 2020-04-06 00:00:00 UTC | New Drugs Approved In The Month Of March | ABBV | https://www.nasdaq.com/articles/new-drugs-approved-in-the-month-of-march-2020-04-06 | null | null | (RTTNews) - The novel coronavirus that originated in the city of Wuhan in China last December, has spread to almost all the countries, affecting millions. As of this writing, the number of confirmed cases is 1,274,346 and the death toll is 69,480.
Almost all international airports have been closed around the world and ... | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Almost all international airports have been closed around the world and many countries are enforcing lock downs among its nationals to reduce the spread of the virus. Sarclisa, a monoclonal an... | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Last week, Sanofi received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sarclisa. Zeposia The FDA approved Zeposia (ozanimod)... | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Sarclisa, a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, is approved to be used in combination with Bristol-Myers Squibb's pomalidomide and steroid dexamethas... | Allergan, in June, had announced that it was being acquired by AbbVie Inc.(ABBV) for approximately $63 billion, cash and stock. Let us take a look at the new drugs that were approved. Sarclisa The FDA approved Sarclisa (isatuximab-irfc),developed by Sanofi (SNY) on March 2, 2020. |
24,631 | 2020-04-06 00:00:00 UTC | Why AbbVie Stock Tanked in March | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-tanked-in-march-2020-04-06 | null | null | What happened
Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. This large-cap biopharma thus lost approximately $20 billion in market capitalization last month.
On the bright side, AbbVie's stock did perform modestly better... | What happened Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. On the bright side, AbbVie's stock did perform modestly better than both the Dow Jones Industrial Average and the S&P 500 in March. What's more, AbbVie's shares... | See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell owns shares of AbbVie. What happened Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a staggering 11.1% in March, according to data from S&P Global Market Intelligence. On the bright side, AbbVie's stock did perform modestly bett... | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of March 18, 202... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell owns shares of AbbVie. What happened Shares of AbbVie (NYSE: ABBV), a blue-chip biopharma, fell by a stagg... |
24,632 | 2020-04-05 00:00:00 UTC | Why AbbVie Is a Fantastic Dividend Stock to Buy During the Coronavirus Market Crash | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-a-fantastic-dividend-stock-to-buy-during-the-coronavirus-market-crash-2020 | null | null | It's hard to be optimistic when there seems to be nothing but bad news. The numbers of individuals infected with novel coronavirus disease COVID-19 continue to climb. Hospitals are overwhelmed. People are losing their jobs as their employers shut down. And stocks are in a bear market for the first time in over a decade... | If the stock price of a profitable, well-respected company like AbbVie falls to a certain point where its valuation is simply too attractive to pass up, investors will rush in to buy shares. Some good news Even with the headwinds for Humira, Wall Street analysts project that AbbVie will be able to grow its earnings by ... | An impressive dividend track record AbbVie's dividend yield of close to 6.3% will probably make your mouth water. The company's steadfast commitment to raising its dividend makes me confident that AbbVie will keep its impressive dividend track record going. A compelling valuation AbbVie's share price has declined quite... | I think that AbbVie (NYSE: ABBV) is a fantastic dividend stock to buy in the midst of the coronavirus market crash. The company's steadfast commitment to raising its dividend makes me confident that AbbVie will keep its impressive dividend track record going. If the stock price of a profitable, well-respected company l... | I think that AbbVie (NYSE: ABBV) is a fantastic dividend stock to buy in the midst of the coronavirus market crash. An impressive dividend track record AbbVie's dividend yield of close to 6.3% will probably make your mouth water. Including the time when it was a part of Abbott Labs, AbbVie has increased its dividend fo... |
24,633 | 2020-03-31 00:00:00 UTC | 19 Dividend Aristocrats That Have Gone on Deep Discount | ABBV | https://www.nasdaq.com/articles/19-dividend-aristocrats-that-have-gone-on-deep-discount-2020-03-31 | null | null | In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.
During the 2010s, these high-quality stocks returned an average of 14.75% per year, b... | SEE ALSO: 64 Dividend Stocks You Can Count On in 2020 AbbVie Market value: $111.1 billion Dividend yield: 6.3% Performance since 2/19/20: -20.1% (vs. -22.4% for the S&P 500) AbbVie (ABBV, $75.24) expects that its pending $63 billion merger with Allergan (AGN) will offset slowing growth of its blockbuster drug Humira. A... | ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth... | ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth... | ABBV shares look cheap at just 7.5 times forward-looking earnings estimates, which is modest compared to the company's historical average forward P/E of 12. Dividend growth investors will like AbbVie's 48 consecutive years of payout hikes; a conservative payout ratio of 48% that provides flexibility for dividend growth... |
24,634 | 2020-03-30 00:00:00 UTC | Monday 3/30 Insider Buying Report: ABBV, NKE | ABBV | https://www.nasdaq.com/articles/monday-3-30-insider-buying-report%3A-abbv-nke-2020-03-30 | null | null | Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider b... | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. AbbVie is trading up about 3.1% on the day Monday. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed ... | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed herein are the views and opinions of the author and... | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. AbbVie is trading up about 3.1% on the day Monday. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed ... | At AbbVie, a filing with the SEC revealed that on Monday, VP, Controller Brian L. Durkin purchased 3,750 shares of ABBV, for a cost of $68.20 each, for a total investment of $255,755. AbbVie is trading up about 3.1% on the day Monday. VIDEO: Monday 3/30 Insider Buying Report: ABBV, NKE The views and opinions expressed ... |
24,635 | 2020-03-30 00:00:00 UTC | 4 Reasons Drug Stocks Are a Buy Right Now | ABBV | https://www.nasdaq.com/articles/4-reasons-drug-stocks-are-a-buy-right-now-2020-03-30 | null | null | The emerging coronavirus pandemic highlights the world's dependence on pharmaceutical and biotech companies to produce drugs and vaccines to help overcome all types of illness. This outbreak may bring new appreciation for the industry. Here we explore four reasons that investors should consider drug stocks currently in... | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. The emerging coronavirus pandemic highlights the world's dependence on pharmaceutical and biotech companies to produc... | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. In fact, its top ten holdings, including Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX), Amgen... | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. Big pharmaceutical companies, smaller specialty pharma, and biotech companies will continue to deliver medicines to t... | The stocks of big pharmaceutical companies like AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) are down 20% to 30% from peak prices in the past year. Big pharmaceutical companies, smaller specialty pharma, and biotech companies will continue to deliver medicines to t... |
24,636 | 2020-03-29 00:00:00 UTC | Have $1,000 to Invest? 3 Great High-Yield Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/have-%241000-to-invest-3-great-high-yield-dividend-stocks-to-buy-right-now-2020-03-29 | null | null | It's raining gold. That's probably how Warren Buffett would summarize the stock market crash. Buffett wrote to Berkshire Hathaway shareholders in 2010: "Big opportunities come infrequently. When it's raining gold, reach for a bucket, not a thimble."
The problem for many investors, though, is that they don't exactly ha... | There's one big knock against AbbVie: Its dependence on Humira, the company's top-selling immunology drug that's already losing market share in Europe and will face biosimilar competition in the U.S. in three years. However, AbbVie's other products and pipeline candidates along with its pending acquisition of Allergan ... | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) doesn't have the long history of dividend increases that AbbVie does. AbbVie AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. AbbVie easily surpasses that threshold, with a sterling track record of 47... | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) doesn't have the long history of dividend increases that AbbVie does. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Chevron. AbbVie AbbVie (NYSE... | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Chevron. AbbVie AbbVie (NYSE: ABBV) belongs to an elite group of stocks known as Dividend Aristocrats. AbbVie easily surpasses that threshold, with a sterling track record of 47 ye... |
24,637 | 2020-03-27 00:00:00 UTC | 2 Dividend Stocks Trading at Dirt-Cheap Prices | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-trading-at-dirt-cheap-prices-2020-03-27 | null | null | The COVID-19 pandemic is affecting our social lives, as governmental authorities in most U.S. states have implemented drastic measures -- including social distancing -- to mitigate the spread of the disease. The outbreak also continues to wreak havoc on equity markets. Year to date, the S&P 500 is down by 20% (at writi... | The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats several autoimmune disorders including plaque psoriasis and rheumatoid arthritis -- have been declining in Europe because of competition from biosimilars. In particular, here are two that y... | ABBV Dividend Yield data by YCharts AbbVie's dividend yield is currently 6.18%, and the company has raised its dividends by 195% since it was created in 2013. In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed pa... | In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed particularly well of late. The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats sev... | In particular, here are two that you can currently buy for a discount: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie Pharma giant AbbVie hasn't performed particularly well of late. The reason behind AbbVie's poor performance in 2019 isn't a secret: Sales of the company's blockbuster drug Humira -- which treats sev... |
24,638 | 2020-03-27 00:00:00 UTC | 3 Dirt-Cheap Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dirt-cheap-healthcare-stocks-to-buy-right-now-2020-03-27 | null | null | We're living out the memorable opening line of Charles Dickens' classic novel A Tale of Two Cities. It really is both the best of times and the worst of times.
Identifying what makes this the worst of times is easy. The coronavirus pandemic has arguably caused the greatest disruption to everyday life since World War II... | AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. However, AbbVie has been planning for this eventuality for years. | AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. However, AbbVie has been planning for this eventuality for years. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Bristol-Myers Squibb. AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but t... | AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than 9 times expected earnings. That kind of low valuation might make sense for a company likely to experience an earnings decline, but that's not the case for AbbVie. However, AbbVie has been planning for this eventuality for years. |
24,639 | 2020-03-26 00:00:00 UTC | ABBV May 8th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-may-8th-options-begin-trading-2020-03-26 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 8th contracts and identified one put and one call contract of particular interest.
The put contract at... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red: Considering the fact that the $73.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $70.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $73.50 strike price has a current bid of $2.50. Below is a chart showing ABBV'... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 8th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $73.50 strike highlighted in red: Considering ... |
24,640 | 2020-03-25 00:00:00 UTC | 3 Reasons Pharma Stocks Are a Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-reasons-pharma-stocks-are-a-buy-right-now-2020-03-25 | null | null | Few sectors have escaped the gravity of the investing black hole known as the coronavirus pandemic. Nearly every stock has plunged, with a 20% drop constituting a relatively mild decline. There have been bounces, including renewed buying on anticipation of a huge coronavirus rescue bill. However, it's impossible to kno... | And while AbbVie faces sales erosion for Humira due to biosimilar competition, its new immunology drugs Rinvoq and Skyrizi and the pending acquisition of Allergan should help considerably. AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock... | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. | See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. | AbbVie (NYSE: ABBV), for example, boasts a super-low forward earnings multiple of 8.6. Investors who buy AbbVie right now will lock in fantastic dividend payments going forward. Considering that AbbVie has raised its dividend for an impressive 47 consecutive years, it's likely the dividend will keep moving higher. |
24,641 | 2020-03-25 00:00:00 UTC | Analysts Predict 34% Upside For TOK | ABBV | https://www.nasdaq.com/articles/analysts-predict-34-upside-for-tok-2020-03-25 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI Kokusai ETF (Symbo... | iShares MSCI Kokusai ETF TOK $53.81 $72.22 34.22% Melco Resorts & Entertainment Ltd MLCO $13.86 $28.35 104.55% Equifax Inc EFX $113.66 $159.00 39.89% AbbVie Inc ABBV $67.49 $94.40 39.87% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of T... | Three of TOK's underlying holdings with notable upside to their analyst target prices are Melco Resorts & Entertainment Ltd (Symbol: MLCO), Equifax Inc (Symbol: EFX), and AbbVie Inc (Symbol: ABBV). Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/sha... | Similarly, EFX has 39.89% upside from the recent share price of $113.66 if the average analyst target price of $159.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $94.40/share, which is 39.87% above the recent price of $67.49. Three of TOK's underlying holdings with notable u... | iShares MSCI Kokusai ETF TOK $53.81 $72.22 34.22% Melco Resorts & Entertainment Ltd MLCO $13.86 $28.35 104.55% Equifax Inc EFX $113.66 $159.00 39.89% AbbVie Inc ABBV $67.49 $94.40 39.87% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of T... |
24,642 | 2020-03-25 00:00:00 UTC | Insiders Buy the Holdings of DEW ETF | ABBV | https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-dew-etf-2020-03-25 | null | null | A look at the weighted underlying holdings of the WisdomTree Global High Dividend Fund (DEW) shows an impressive 12.5% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2... | AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. The table below details t... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $67.49 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the rece... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $67.49 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the rece... | AbbVie Inc (Symbol: ABBV), which makes up 2.14% of the WisdomTree Global High Dividend Fund (DEW), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,238,180 worth of ABBV, making it the #5 largest holding. The table below details t... |
24,643 | 2020-03-24 00:00:00 UTC | Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet | ABBV | https://www.nasdaq.com/articles/top-notch-vaccine-technology-makes-ibio-stock-a-smart-bet-2020-03-24 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
iBio (NYSEMKT:IBIO) is one of the few stocks up for the year, with a 350% return so far. Keep in mind that the shares had climbed as high as $3.40, but are now at $1.10. IBIO stock is one of those small-cap names that — not too long ago — was mostly forgott... | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. 7 Stocks Insiders Are Buying Big Amid the Market Panic The vaccine candidate is based on the research of Dr. Kevin Wang... | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) is one of the few stocks up for the ... | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) is one of the few stocks up for the ... | And yes, there are numerous companies, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD), that are focused on finding a vaccine for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) is one of the few stocks up for the ... |
24,644 | 2020-03-24 00:00:00 UTC | Better Buy: AbbVie vs. Biogen | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-03-24 | null | null | For investors seeking stocks to put into their portfolios for the long term, healthcare's a great place to look. It's an industry where there's always going to be significant demand, especially as the population ages. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the in... | Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. The deal, which the companies expect will close in May ... | Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. On its own, AbbVie is a solid healthcare stock; its str... | Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. AbbVie is the safer buy, but growth investors may opt f... | On its own, AbbVie is a solid healthcare stock; its strong, consistent revenue has topped $30 billion for the past two years. AbbVie is the safer buy, but growth investors may opt for Biogen A quick look at how these two stocks have performed over the past year shows little difference, despite their very different path... |
24,645 | 2020-03-23 00:00:00 UTC | Monday's ETF with Unusual Volume: DDIV | ABBV | https://www.nasdaq.com/articles/mondays-etf-with-unusual-volume%3A-ddiv-2020-03-23 | null | null | The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume in afternoon trading Monday, with over 176,000 shares traded versus three month average volume of about 26,000. Shares of DDIV were off about 4.4% on the day.
Components of that ETF with the highest volume on Monday were JP Morgan Cha... | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume i... | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume i... | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. The First Trust Dorsey Wright Momentum & Dividend ETF is seeing unusually high volume i... | Components of that ETF with the highest volume on Monday were JP Morgan Chase, trading off about 2.9% with over 16.2 million shares changing hands so far this session, and Abbvie, off about 4.8% on volume of over 8.6 million shares. Ryman Hospitality Properties is the component faring the best Monday, higher by about 1... |
24,646 | 2020-03-23 00:00:00 UTC | AbbVie Becomes Oversold (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-becomes-oversold-abbv-2020-03-23 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and b... | A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in i... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and b... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $64.33 per share. A bullish investor could look at ABBV's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and b... |
24,647 | 2020-03-23 00:00:00 UTC | These 3 Dividend Stocks Are Now Yielding Up to 20% | ABBV | https://www.nasdaq.com/articles/these-3-dividend-stocks-are-now-yielding-up-to-20-2020-03-23 | null | null | The coronavirus pandemic is having a significant impact on the markets. This month, the Dow Jones dropped below 20,000 -- the lowest it's been in three years. And when share prices fall, dividend yields rise.
For dividend investors, it could be an opportune time to buy. But investors still need to be careful as a high ... | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). AbbVie's future looks strong, and with healthcare in the spotlight as a result of the coronavirus and a possible shortage of drugs, the company's business shouldn't be a c... | AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). In the company's year-end results, which AbbVie released on Feb. 7, it reported diluted earnings per ... | AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). In the company's year-end results, which AbbVie released on Feb. 7, it reported diluted earnings per ... | AbbVie is the best buy of the three, and it's the most likely to continue paying its dividend in 2020 and beyond. AbbVie AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories ... |
24,648 | 2020-03-22 00:00:00 UTC | You Won't Regret Buying These 3 Bargain Stocks | ABBV | https://www.nasdaq.com/articles/you-wont-regret-buying-these-3-bargain-stocks-2020-03-22 | null | null | Two music legends, Frank Sinatra and Elvis Presley, each had a big hit with the song "My Way." The lyrics of the song include a line that says, "Regrets, I've had a few. But then again, too few to mention."
I don't know about you, but I've had more regrets with investing than I'd care to mention. And most of them aren... | I think AbbVie will deliver solid share price appreciation over the long run, but it won't have to do too much to provide a market-beating total return with its awesome dividend program. AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. There have been some concerns about how AbbVie will fare after ... | AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. More importantly, momentum for AbbVie's other drugs is reducing its dependence on Humira. | Pfizer Pfizer (NYSE: PFE) is more expensive than AbbVie or Bristol Myers Squibb. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. | AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. More importantly, momentum for AbbVie's other drugs is reducing its dependence on Humira. |
24,649 | 2020-03-22 00:00:00 UTC | Should You Really Buy Stocks Now or Wait a While Longer? | ABBV | https://www.nasdaq.com/articles/should-you-really-buy-stocks-now-or-wait-a-while-longer-2020-03-22 | null | null | Anyone who lived through the financial crisis of 2008 and 2009 knows that the turmoil during that period presented a fantastic opportunity to buy stocks. Not everyone realized it at the time, though. There was a lot of fear and trepidation about what could happen next.
It's a similar story today. Most investors probabl... | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. Anyone who lived through the financial crisis of 2008 and 2009 knows that the turmoil during that period presented a fantast... | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. You can get both a bargain and a sky-high dividend yield with Enterprise Products Partners (NYSE: EPD). | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. Most investors probably realize that the stock market crash caused by the coronavirus pandemic will in retrospect be one of ... | AbbVie (NYSE: ABBV) is one of my favorite dividend stocks to buy right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie and Guardant Health. Should you really buy stocks now? |
24,650 | 2020-03-20 00:00:00 UTC | 3 Dividend Stocks Ideal for Retirees With Money To Invest In The Bear Market | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-ideal-for-retirees-with-money-to-invest-in-the-bear-market-2020-03-20 | null | null | Dividend stocks provide many people with a viable option for retirement income. The S&P 500 average dividend stands at approximately 2.4%, exceeding what most bank-related instruments yield in a savings account. Moreover, the return on many dividend stocks dramatically exceeds the S&P 500's average price appreciation. ... | AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. AbbVie traded as high as $125.86 per share in 2018. However, AbbVie did not rest on its laurels with Humira. | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. AbbVie traded as high as $125.86 per sh... | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Will Healy owns shares of AbbVie. AbbV... | AbbVie AbbVie (NYSE: ABBV) finds itself in a transition phase. AbbVie traded as high as $125.86 per share in 2018. However, AbbVie did not rest on its laurels with Humira. |
24,651 | 2020-03-19 00:00:00 UTC | Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play | ABBV | https://www.nasdaq.com/articles/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-2020-03-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
iBio (NYSEMKT:IBIO) stock spent much of the last year trading as a penny stock. That changed at the end of February 2020 when IBIO stock surged to as high as $3.40.
Source: Shutterstock
Though the stock lasted only briefly there, investors rushed into the s... | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. iBio uses modified “relatives of the tobacco plant to grow viral proteins for vaccines.” Beijing CC-Pharming will then wor... | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) stock spent much of the last year tradi... | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) stock spent much of the last year tradi... | When other big firms like AbbVie (NYSE:ABBV), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are developing therapies for the coronavirus from China, IBIO stock looks more like a gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips iBio (NYSEMKT:IBIO) stock spent much of the last year tradi... |
24,652 | 2020-03-19 00:00:00 UTC | Abbvie's HIV Drug Kaletra Fails to Help COVID-19 Patients | ABBV | https://www.nasdaq.com/articles/abbvies-hiv-drug-kaletra-fails-to-help-covid-19-patients-2020-03-19 | null | null | The coronavirus that causes COVID-19 and HIV are both RNA-based viruses, so there was hope that current HIV medications might be able to speed recovery of patients with COVID-19. Unfortunately, early evidence suggests that just isn't the case.
On Monday, Johnson & Johnson (NYSE: JNJ) said there was no evidence that its... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any b... | And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it ... | And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it ... | And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (NYSE: ABBV) HIV drug Kaletra plus standard of care wasn't any better than the standard of care. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it ... |
24,653 | 2020-03-18 00:00:00 UTC | Is This 1 Healthcare Stock Coronavirus-Proof? | ABBV | https://www.nasdaq.com/articles/is-this-1-healthcare-stock-coronavirus-proof-2020-03-18 | null | null | On March 11, the Dow Jones slid by over 1,400 points -- or about 5.8% of its value at the time -- and fell 20% from its most recent high, thus officially entering bear market territory. The culprit? The COVID-19 pandemic that continues to spread worldwide. According to Johns Hopkins University, as of March 17, there ar... | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. On March 11, the Dow Jones slid by over 1,400 points -- or about 5.8% of its value at the time -- ... | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. Since people don't choose when they get sick -- or for that matter, when they will need to take dr... | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. Why Johnson & Johnson is performing better than others While shares of Johnson & Johnson are down ... | Furthermore, Johnson & Johnson's blockbuster drug Stelara -- which treats several immune system conditions such as plaque psoriasis and Crohn's disease -- has to contend with products such as AbbVie's (NYSE: ABBV) Humira. While this pandemic will likely keep affecting the stock market, some stocks seem to be handling t... |
24,654 | 2020-03-18 00:00:00 UTC | AbbVie Strikes Deal With the FTC to Move Its Allergan Acquisition Forward | ABBV | https://www.nasdaq.com/articles/abbvie-strikes-deal-with-the-ftc-to-move-its-allergan-acquisition-forward-2020-03-18 | null | null | In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. AbbVie likely decided to pursue the massive acquisition in part to decrease its reliance on its best-selling drug Humira, sales of which have been declining in Europe due to competition from b... | AbbVie likely decided to pursue the massive acquisition in part to decrease its reliance on its best-selling drug Humira, sales of which have been declining in Europe due to competition from biosimilars. In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $... | In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued... | In a letter sent to the U.S. Federal Trade Commission (FTC) in September, a coalition of consumer groups and unions expressed their concerns that AbbVie's acquisition of Allergan "will likely harm consumers." Selling assets to reduce the anticompetitive risks AbbVie and Allergan have agreed to divest some of their asse... | However, AbbVie now says it expects the deal to close in May. Still, the good news is that AbbVie should not encounter any more obstacles now that is has reached a deal with the FTC. In June, AbbVie (NYSE: ABBV) made a bid to purchase Allergan (NYSE: AGN) in a cash and stock transaction valued at $63 billion. |
24,655 | 2020-03-18 00:00:00 UTC | Health Care Sector Update for 03/18/2020: VKTX,BMRA,ABBV,AGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-18-2020%3A-vktxbmraabbvagn-2020-03-18-0 | null | null | Top Health Care Stocks
JNJ -4.58%
PFE -2.57%
ABT -3.65%
MRK -6.47%
AMGN -4.01%
Health care stocks stabilized somewhat Wednesday afternoon, with the NYSE Health Care Index declining 6.5% in late trade while the SPDR Health Care Select Sector ETF was down 6.7%. The Nasdaq Biotechnology index also was falling 4.8% shortly... | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. In other sector news: (+) Biomerica (BMRA) more than quadrupl... | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Top Health Care Stocks Health care stocks stabilized somewhat... | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Health care stocks stabilized somewhat Wednesday afternoon, w... | (-) AbbVie (ABBV) slid 3% after agreeing to divest a monoclonal antibody used to treat autoimmune diseases along with two pancreatic enzyme treatments all owned by Allergen (AGN) to win regulatory approval for its proposed acquisition of the Irish drugmaker. Health care stocks stabilized somewhat Wednesday afternoon, w... |
24,656 | 2020-03-17 00:00:00 UTC | Noteworthy ETF Outflows: VT, HON, ABBV, LLY | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-vt-hon-abbv-lly-2020-03-17 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $150.1 million dollar outflow -- that's a 1.5% decrease week over week (from 172,217,177 to 169,638,922). Am... | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one ye... | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one ye... | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of VT, in trading today Honeywell International Inc (Symbol: HON) is up about 4.5%, AbbVie Inc (Symbol: ABBV) is down about 3.7%, and Lilly (Eli) & Co (Symbol: LLY) is up by about 4.4%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one ye... |
24,657 | 2020-03-17 00:00:00 UTC | Coronavirus Correction: 3 Must-Own Dividend Stocks | ABBV | https://www.nasdaq.com/articles/coronavirus-correction%3A-3-must-own-dividend-stocks-2020-03-17 | null | null | The coronavirus is smashing stock markets across the globe. In nearly every sector and asset class, valuations are tumbling as investors wrestle with the economic impact of this deadly virus. The offshoot of this "sell first, ask questions later" mentality is that a handful of stocks are getting unfairly punished right... | AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biopharmaceutical play AbbVie's shares are down by 16% so far this year. First off, AbbVie's shares are now trading a... | AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biopharmaceutical play AbbVie's shares are down by 16% so far this year. First off, AbbVie's shares are now trading a... | See the 10 stocks *Stock Advisor returns as of December 1, 2019 George Budwell owns shares of AbbVie and Pfizer. AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biop... | So, once the market gets back to normal a few months from now, AbbVie's stock should quickly regain its footing. AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are three top biopharmas investors may want to look to for safe haven in this chaotic environment. AbbVie: An ultra-high yield biop... |
24,658 | 2020-03-16 00:00:00 UTC | 7 Biotech Stocks to Buy and Hold in 2020 | ABBV | https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-and-hold-in-2020-2020-03-16 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
[Editor’s note: “7 Biotech Stocks to Buy and Hold in 2020” was previously published in December 2019. It has since been updated to include the most relevant information available.]
If it were not for the surge in stock prices in the fourth quarter, biotechn... | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. This is offset by the launch of Vumerity, a drug also used to treat people with relapsing forms of MS. 7 Drowning Energy Stocks to Avoid for... | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. Amgen (AMGN) Source: Michael Vi / Shutterstock.com Amgen (NASDAQ:AMGN) trades with analyst price targets that average $248. | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. InvestorPlace - Stock Market News, Stock Advice & Trading Tips [Editor’s note: “7 Biotech Stocks to Buy and Hold in 2020” was previously pub... | Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. If approved, it will compete with AbbVie’s (NYSE:ABBV) Humira. So, biotech companies that raise prices to offset higher research and development costs may do so in 2020. |
24,659 | 2020-03-16 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson-2020-03-16 | null | null | One company produces the top-selling pharmaceuticals in the world. The other is a household name that offers various consumer health products as well as pharmaceutical products. Both are dealing with some hurdles and challenges.
We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Are either of th... | AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). AbbVie AbbVie underperformed the broader market last year, down 3.9% in a year when the S... | Quarterly earnings were boosted by solid U.S. sales of AbbVie's top-selling drug, Humira, which treats rheumatoid arthritis. AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. We're talking about AbbVie (NYSE: ABBV)... | Johnson & Johnson Johnson & Johnson is coming off a better year than AbbVie, at least as far as shareholders are concerned. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). AbbVie AbbVie underperformed the broader market last year, down 3.9% in a year when the S&P 500 returned 28.9%. | AbbVie also had strong sales from Imbruvica, a cancer drug, which saw global net revenues climb 28.9% to $1.3 billion in the quarter, an increase of 28.9%. We're talking about AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). AbbVie AbbVie underperformed the broader market last year, down 3.9% in a year when the S... |
24,660 | 2020-03-15 00:00:00 UTC | 3 Great Dividend Stocks to Buy If You're Sick and Tired of Hearing About the Coronavirus | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-if-youre-sick-and-tired-of-hearing-about-the-coronavirus | null | null | It's pretty much nothing but coronavirus and COVID-19 coverage non-stop everywhere you turn. Quite frankly, that's the way it should be. The pandemic is serious and requires sober-minded efforts to minimize its effects. But I suspect that many Americans are feeling COVID-19 information overload right now.
There's a gr... | AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. AbbVie's dividend now yields a mouthwatering 6%. And as for that infectious disease that shall not be named, it shouldn't have any effect on AbbVie's business. | Medical Properties Trust Not every great dividend stock is as large and well-known as AbbVie and AT&T. AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. AbbVie's dividend now yields a mouthwatering 6%. | Medical Properties Trust Not every great dividend stock is as large and well-known as AbbVie and AT&T. AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. AbbVie's dividend now yields a mouthwatering 6%. | AbbVie's dividend now yields a mouthwatering 6%. AbbVie AbbVie's (NYSE: ABBV) shares have fallen during the overall market sell-off, although not as much as the S&P 500 index has. And as for that infectious disease that shall not be named, it shouldn't have any effect on AbbVie's business. |
24,661 | 2020-03-12 00:00:00 UTC | Roche : EC Oks Venclyxto-Gazyvaro For Adults With Chronic Lymphocytic Leukaemia | ABBV | https://www.nasdaq.com/articles/roche-%3A-ec-oks-venclyxto-gazyvaro-for-adults-with-chronic-lymphocytic-leukaemia-2020-03-12 | null | null | (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or venetoclax in combination with Gazyvaro or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia or CLL.
Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly comm... | Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or ... | Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or ... | It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. Venclexta/Venclyxto is being developed by AbbVie and Roche. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or ... | Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, under the brand name Venclexta, and commercialised by AbbVie outside of the US. (RTTNews) - Roche (RHHBY) said that the European Commission has approved Venclyxto or ... |
24,662 | 2020-03-12 00:00:00 UTC | May 1st Options Now Available For AbbVie | ABBV | https://www.nasdaq.com/articles/may-1st-options-now-available-for-abbvie-2020-03-12 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 1st contracts and identified one put and one call contract of particular interest.
The put contract at th... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red: Considering the fact that the $81.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $81.00 strike price has a current bid of $2.90. Below is a chart showing ABBV'... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 1st contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.00 strike highlighted in red: Considering ... |
24,663 | 2020-03-11 00:00:00 UTC | Health Care Sector Update for 03/11/2020: AYTU,ONCT,JNJ,ABBV,DXC,SEEL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-11-2020%3A-aytuonctjnjabbvdxcseel-2020-03-11 | null | null | Top Health Care Stocks
JNJ -6.06%
PFE -7.31%
ABT -3.47%
MRK -3.37%
AMGN -3.74%
Health care stocks fell Wednesday, with the NYSE Health Care Index declining about 4.9% while the SPDR Health Care Select Sector ETF was down 3.7%. The Nasdaq Biotechnology index was dropping 4.9% this afternoon.
Among health care stocks mov... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle c... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle c... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle c... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 17% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle c... |
24,664 | 2020-03-11 00:00:00 UTC | Health Care Sector Update for 03/11/2020: SEEL,DXC,ONCT,JNJ,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-11-2020%3A-seeldxconctjnjabbv-2020-03-11 | null | null | Top Health Care Stocks
JNJ -5.77%
PFE -5.80%
ABT -4.03%
MRK -3.17%
AMGN -3.05%
Health care stocks were falling, with the NYSE Health Care Index declining about 4.0% while the SPDR Health Care Select Sector ETF was down 3.2%. The Nasdaq Biotechnology index was dropping 3.9% this afternoon.
Among health care stocks movin... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle ... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle ... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle ... | In other sector news: (+) Oncternal Therapeutics (ONCT) rose 3.1% after the company reported encouraging interim data from phase I/II testing of a combination of its cirmtuzumab monoclonal antibody with Johnson & Johnson's (JNJ) and AbbVie's (ABBV) ibrutinib cancer medication in patients with relapsed/refactory mantle ... |
24,665 | 2020-03-10 00:00:00 UTC | AbbVie to Test HIV Drug as a Potential Coronavirus Treatment | ABBV | https://www.nasdaq.com/articles/abbvie-to-test-hiv-drug-as-a-potential-coronavirus-treatment-2020-03-10 | null | null | As the COVID-19 epidemic continues to spread worldwide, the race to find treatments and vaccines for the disease is heating up. Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19.
Kaletra is a combination of lopinavir and rit... | Among those searching for solutions is AbbVie (NYSE: ABBV), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical da... | With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. Among those searching for solutions is AbbVie (NYSE: ... | With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. Among those searching for solutions is AbbVie (NYSE: ... | With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (NASDAQ: GILD), Inovio Pharmaceuticals (NASDAQ: INO), and Novavax (NASDAQ: NVAX), all of which are racing to find an effective response to the novel coronavirus. Among those searching for solutions is AbbVie (NYSE: ... |
24,666 | 2020-03-10 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 3/10/2020 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-3-10-2020-2020-03-10 | null | null | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
CIVISTA BANCSHARES INC (CIVB) is a small-cap value stock in the Reg... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company serves various end markets, including petroleum refining, c... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates through segments, including Construction Industrie... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates through segments, including Construction Industrie... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's products include systems, and installed base products and... |
24,667 | 2020-03-09 00:00:00 UTC | AbbVie: Chinese Media Reports Claim HIV Medicine Effective In COVID-19 Treatment | ABBV | https://www.nasdaq.com/articles/abbvie%3A-chinese-media-reports-claim-hiv-medicine-effective-in-covid-19-treatment-2020-03 | null | null | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment.
But, the company said it does not have access to Chinese clinical information and therefore cannot confirm its accuracy.
The company said it d... | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. The company also noted that it is working with global health authorit... | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. The company also noted that it is working with global health authorit... | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. The company also noted that it is working with global health authorit... | (RTTNews) - AbbVie said Monday that unconfirmed media reports from China claimed that the HIV medicine, Kaletra/Aluvia or lopinavir/ritonavir is effective in COVID-19 treatment. AbbVie was down $5.32 or 5.99 percent to $83.50 in the pre-Market trade. But, the company said it does not have access to Chinese clinical inf... |
24,668 | 2020-03-08 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch in the Coronavirus Sell-Off | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-in-the-coronavirus-sell-off-2020-03-08 | null | null | In a world where investors struggle to earn decent returns from fixed-income instruments, dividend stocks have emerged as a strategy for earning higher returns. The average dividend yield for the S&P 500 is just over 1.9%, dramatically higher than the 0.09% in interest people earn in a savings account on average.
Moreo... | AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. Moreover, AbbVie has shown signs of recovery in recent months. | AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. Moreover, AbbVie has shown signs of recovery in recent months. | Moreover, Dividend Aristocrats such as AbbVie tend to continue dividend hikes unless the company's financial condition makes payout raises untenable. AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned t... | AbbVie AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. However, AbbVie looks positioned to move on from Humira. Moreover, AbbVie has shown signs of recovery in recent months. |
24,669 | 2020-03-06 00:00:00 UTC | Is There a Cure for the SARS-CoV-2 Coronavirus? | ABBV | https://www.nasdaq.com/articles/is-there-a-cure-for-the-sars-cov-2-coronavirus-2020-03-06 | null | null | There have been over 100,000 confirmed cases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and more than 3,400 people have died from the disease, according to data tracked by Johns Hopkins University's Center for Systems Science and Engineering. Unfortunately, there is no cure for the disease yet... | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. Unfortunately, there is no cure for the disease yet, but multiple drugmakers are working on treatments that might help fight off the coronavirus or prevent infections altogether. Because it takes awhile to ... | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. Gilead Sciences (NASDAQ: GILD) has started two clinical trials testing remdesivir, which had only limited success as an Ebola treatment, in patients with COVID-19. Both Moderna (NASDAQ: MRNA) and Inovio Pha... | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. Gilead Sciences (NASDAQ: GILD) has started two clinical trials testing remdesivir, which had only limited success as an Ebola treatment, in patients with COVID-19. Johnson & Johnson (NYSE: JNJ) has donated ... | AbbVie's (NYSE: ABBV) HIV drug Kaletra has also been tested on patients with some reports of patients recovering. The treatments weren't part of a clinical trial, so there's no way of knowing if the drug helped the patients or if they would have recovered on their own. The Motley Fool recommends Johnson & Johnson. |
24,670 | 2020-03-06 00:00:00 UTC | AbbVie : EU Approves Change To Marketing Authorization For Maviret | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-eu-approves-change-to-marketing-authorization-for-maviret-2020-03-06 | null | null | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection.
Maviret was alread... | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatme... | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatme... | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatme... | (RTTNews) - AbbVie (ABBV) said Friday that the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. "A shorter treatme... |
24,671 | 2020-03-05 00:00:00 UTC | 3 Top Large-Cap Stocks to Buy in March | ABBV | https://www.nasdaq.com/articles/3-top-large-cap-stocks-to-buy-in-march-2020-03-05 | null | null | February is finally in the rearview mirror, and none too soon. While it started out on the right foot, it ended in disaster. The last week of the month dished out an 11.5% loss for the S&P 500, translating into an 8.4% setback for the full month. It was the worst single week for stocks since 2008 when we were in the th... | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. | AbbVie (ABBV): $134 billion market cap Through 2017, AbbVie (NYSE: ABBV) was practically bulletproof. It can't carry all of AbbVie's weight on its own. Patent expirations and maturing drugs are nothing new to the big names in the business, however, including AbbVie. |
24,672 | 2020-03-05 00:00:00 UTC | 3 Dividend Stocks to Ride out the Market Volatility | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-ride-out-the-market-volatility-2020-03-05 | null | null | Should dividend stocks have a place in your portfolio as the market continues to churn? The from China is delivering a level of uncertainty that investors despise. Aside from the understandable â if perhaps overstated â health concerns, investors are trying to evaluate the impact on global supply chains. Inve... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. The rheumatoid arthritis drug is responsible for nearly 50% of AbbVieâÂÂs revenue. | Moreover, AbbVie is a dividend aristocrat that has delivered 47 years of consecutive dividend growth. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. | AbbVie stock currently pays an annual dividend of $4.72 per share with a dividend yield of about 5.1%. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be synergy. AbbVie is losing the patent protection on its flagship drug, Humira. | AbbVie stock currently pays an annual dividend of $4.72 per share with a dividend yield of about 5.1%. Moreover, AbbVie is a dividend aristocrat that has delivered 47 years of consecutive dividend growth. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.1% The key word for AbbVie (NYSE:) will be sy... |
24,673 | 2020-03-04 00:00:00 UTC | Is Gilead Sciences the Best Buy in the Coronavirus Sell-Off? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-the-best-buy-in-the-coronavirus-sell-off-2020-03-04 | null | null | Fears over the SARS-CoV-2 virus, and a potential COVID-19 pandemic, are hurting the stock market. On Feb. 27, the S&P 500 fell by about 138 points, representing a 4.4% decline.
The health-related risks posed by COVID-19 are a more significant concern. Fortunately, several pharmaceutical and biotech companies are racing... | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. Although this product has not been performing particularly well -- with its sales remaining practically flat in 2019 compared to 2018 -- the U.S. Food and Drug Administration (FDA) approved Descovy for the prevention of HIV in October... | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. Gilead Sciences' remdesivir shows promise in treating COVID-19 Gilead Sciences is currently looking to develop a treatment for COVID-19, namely a drug called remdesivir, which was previously investigated as a treatment for Ebola but w... | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. Gilead Sciences' remdesivir shows promise in treating COVID-19 Gilead Sciences is currently looking to develop a treatment for COVID-19, namely a drug called remdesivir, which was previously investigated as a treatment for Ebola but w... | Of course, there are other treatments for RA, including AbbVie's (NYSE: ABBV) Humira. With that said, however, other companies are looking to develop treatments or vaccines for COVID-19. For instance, Johnson & Jonhson (NYSE: JNJ) partnered up with the U.S. Department of Health and Human Services (HHS) to develop a vac... |
24,674 | 2020-03-04 00:00:00 UTC | AbbVie To Present At Cowen Health Care Conference; Webcast At 11:20 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-cowen-health-care-conference-webcast-at-11%3A20-am-et-2020-03-04 | null | null | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference.
The event is scheduled to begin at 11:20 AM ET on March 4, 2020.
To access the live webcast, log on to investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily ... | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at ... | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at ... | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at ... | (RTTNews) - AbbVie (ABBV) will participate in the Cowen 40th Annual Health Care Conference. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The event is scheduled to begin at ... |
24,675 | 2020-03-01 00:00:00 UTC | The Best Dividend Aristocrat You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/the-best-dividend-aristocrat-you-can-buy-right-now-2020-03-01 | null | null | Dividends are really good. Dividends that keep coming every year are great. But dividends that keep growing year after year are absolutely fantastic.
There's a category of stocks that delivers such fantastic dividends. Dividend Aristocrats are companies in the S&P 500 that have increased their dividends annually for at... | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. This uni... | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. The comp... | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. Granted,... | Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Air Products & Chemicals. Dividend... |
24,676 | 2020-02-28 00:00:00 UTC | 3 Top Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-right-now-2020-02-28 | null | null | Worry over the growing spread of the novel coronavirus has sent shares of some of my favorite long-term healthcare stocks -- like leading telehealth provider Teladoc Health (NYSE: TDOC) -- skyrocketing in recent weeks against the cascade of red descending on stock markets. For investors, the hope is that a search for a... | Besides inorganic growth, though, AbbVie is also seeing great success with its oncology products, most notably with lymphatic cancer and leukemia treatment Imbruvica, which grew global sales by 30% last year. With patent expirations, merger worry, and global pandemic supply chain disruption keeping stock valuation low,... | Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV). An even steeper discount on big pharma Here's another timely buy for value-oriented investors: AbbVie, which expects its... | See the 10 stocks *Stock Advisor returns as of December 1, 2019 Nicholas Rossolillo and his clients own shares of AbbVie and Teladoc Health. Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva S... | Instead, these three healthcare stocks have my attention, two for their cheap valuation and one for its long-term potential: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), and Veeva Systems (NYSE: VEEV). An even steeper discount on big pharma Here's another timely buy for value-oriented investors: AbbVie, which expects its... |
24,677 | 2020-02-27 00:00:00 UTC | April 9th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/april-9th-options-now-available-for-abbvie-abbv-2020-02-27 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the April 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 9th contracts and identified one put and one call contract of particular interest.
The put contrac... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red: Considering the fact that the $93.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $84.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $93.50 strike price has a current bid of $1.45. Below is a chart showing ABBV'... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 9th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.50 strike highlighted in red: Considerin... |
24,678 | 2020-02-27 00:00:00 UTC | Fighting The Deadly Coronavirus | ABBV | https://www.nasdaq.com/articles/fighting-the-deadly-coronavirus-2020-02-27 | null | null | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China.
A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of sym... | A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of symptoms of the first identified case of COVID-19 on December 8, 2019, there have been more new cases reported from countries outside of China than from China." Nearly 124 studies have either commenced ... | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China. A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of sym... | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China. A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of sym... | (RTTNews) - The new coronavirus, COVID-19, which originated in China, has now spread to least 47 countries, infecting over 81,000 people and killing 3,000 people, with the majority of them in China. A report released by the World Health Organisation on February 25, 2020, says "for the first time, since the onset of sym... |
24,679 | 2020-02-26 00:00:00 UTC | Where Will Johnson & Johnson Be in 1 Year? | ABBV | https://www.nasdaq.com/articles/where-will-johnson-johnson-be-in-1-year-2020-02-26 | null | null | Last year, shares of the big pharma company Johnson & Johnson (NYSE: JNJ) rose by 13%, a performance that trailed that of the pharmaceuticals industry, which was up by 24.7% as measured by the SPDR S&P Pharmaceuticals Index. The S&P 500 -- which was up by about 29% in 2019 -- also outpaced Johnson & Johnson last year.
... | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% y... | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% y... | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. Johnson & Johnson's lineup and pipeline While some of Johnson & Johnson's pharmaceutical products are losing steam, others are on the rise. | For instance, AbbVie's (NYSE: ABBV) Humira is a treatment for plaque psoriasis. AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. The S&P 500 -- which was up by about 29% in 2019 -- also outpaced Johnson & Johnson last year. |
24,680 | 2020-02-26 00:00:00 UTC | If You Invested $5,000 in AbbVie IPO, This Is How Much Money You'd Have Now | ABBV | https://www.nasdaq.com/articles/if-you-invested-%245000-in-abbvie-ipo-this-is-how-much-money-youd-have-now-2020-02-26 | null | null | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). That was the first day the company traded on the New York Stock Exchange. The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would priorit... | The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals. AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in ... | AbbVie produces Humira, the worldʻs top-selling drug. AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013... | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals. AbbVie took with it the rheumatoid arthritis drug Hum... | AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). Th... |
24,681 | 2020-02-26 00:00:00 UTC | What Happens With AbbVie If Its Allergan Buyout Is Blocked? | ABBV | https://www.nasdaq.com/articles/what-happens-with-abbvie-if-its-allergan-buyout-is-blocked-2020-02-26 | null | null | A deal isn't done until the ink dries on the paper. And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet.
AbbVie first announced plans to buy Allergan in June 2019. CEO Rick Gonzalez stated in the company's Q4 conference call earlier this month that the deal was on track t... | Mounting opposition A coalition of consumer groups and trade unions representing over 10 millions subscribers and members oppose AbbVie's takeover of Allergan. The consumer groups and unions are also worried that AbbVie will gain increased bargaining leverage with payers by picking up Allergan's lineup of drugs. And fo... | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. AbbVie's plan B What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? One possible candidate that would be an intriguing pick for AbbVie is Vertex Pharmaceuticals (NASDAQ: VRTX). | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. These groups pointed out in the letter to the FTC that AstraZeneca wasn't able to bring brazikumab to the market in the past and doesn't have the immunology infrastructure in place to be successful against AbbVie. AbbVi... | The problem is that if the FTC scuttles the Allergan buyout, it would probably be opposed to nearly any major deal that AbbVie might want to make. But AbbVie's CF drugs are only in early-stage development, while Vertex claims four FDA-approved CF drugs. It's still possible that the FTC could block AbbVie's acquisition ... |
24,682 | 2020-02-25 00:00:00 UTC | 3 Value Stocks to Buy if the Stock Market Implodes | ABBV | https://www.nasdaq.com/articles/3-value-stocks-to-buy-if-the-stock-market-implodes-2020-02-25 | null | null | The U.S. stock markets took a sizable step backwards yesterday, presumably on the emerging COVID-19 threat. A more careful look, however, suggests that the market was basically due for a correction. After all, most major indices were bumping up against their all-time highs, and valuations across the large-cap space wer... | An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next yea... | The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 time... | The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 time... | An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next yea... |
24,683 | 2020-02-25 00:00:00 UTC | Is It Too Late to Buy High-Flying Galapagos? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-high-flying-galapagos-2020-02-25 | null | null | Galapagos (NASDAQ: GLPG) galloped to all-time highs heading into this week. Although a pullback in the overall market has caused the biotech to give up some of its gains, Galapagos is still up close to 20% year to date and up around 150% over the past 12 months.
Some investors could view Galapagos as valued at a steep ... | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. Gilead and Gal... | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. The experiment... | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. Behind Galapag... | Based on AbbVie's experience with blockbuster drug Humira prior to it losing exclusivity in Europe, I expect somewhere around two-thirds of filgotinib's sales will be made in the U.S. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. But peak annua... |
24,684 | 2020-02-25 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 2/25/2020 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-25-2020-2020-02-25 | null | null | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ROBERT HALF INTERNATIONAL INC. (RHI) is a mid-cap value stock in th... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Martin Marietta Materials, Inc. is a supplier of a... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates through six segments: Vascular North America; Anes... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: The Southern Company (Southern Company) is a holdi... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's business is categorized into Aggregates Business, Cement ... |
24,685 | 2020-02-22 00:00:00 UTC | 5 Ways to Make Your Money Work for You | ABBV | https://www.nasdaq.com/articles/5-ways-to-make-your-money-work-for-you-2020-02-22 | null | null | If you work 40 hours per week for 50 weeks a year, you're toiling for 2,000 hours per year. That's 120,000 minutes of labor, and you're probably not even earning as much as you'd like to earn or think you should earn. One way to enjoy more income -- now and/or later -- is to put some of your money to work for you.
Just... | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. According to the research of University of Pennsylvania professor Jeremy Siegel, the U.S. stock market posted an average annual return of 9.6% between 1926 and 2012, toppi... | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. 10 years $139,716 $156,455 $175,312 15 years $246,725 $293,243 $349,497 20 years $389,927 $494,229 $630,025 25 years $581,564 $789,544 $1.1 million 30 years $838,017 $1.2 ... | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. Pay off debts It might not seem like spending money paying off your debts is a way to make money, but it is. | 5.4% AbbVie 5% Chevron 4.7% Verizon Communications 4.2% Selena Maranjian owns shares of AbbVie, AT&T, Johnson & Johnson, and Verizon Communications. Pay off debts It might not seem like spending money paying off your debts is a way to make money, but it is. |
24,686 | 2020-02-22 00:00:00 UTC | Is Gilead Sciences Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-stock-a-buy-2020-02-22 | null | null | Gilead Sciences (NASDAQ: GILD) has been getting a lot of attention these days for remdesivir, its possible treatment for the coronavirus, which so far has resulted in more than 2,000 deaths. Even though remdesivir could be a plus for the company if approved, there are still too many unknowns to make it a reason for buy... | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. Gilead Sciences... | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. Though a 15% dr... | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. In December, Gi... | The FDA also approved a boxed warning for another rival, AbbVie's upadacitinib, mentioning thrombosis and other risks. While the valuation of nearly 16 is higher than that of Pfizer, which trades at a bit more than 12 times earnings, it's lower than peer AbbVie, which trades at almost 18 times earnings. Even though rem... |
24,687 | 2020-02-21 00:00:00 UTC | Daily Dividend Report: RY,KO,PLD,WRB,ABBV | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-rykopldwrbabbv-2020-02-21 | null | null | Royal Bank of Canada announced today that its board of directors has declared an increase to its quarterly common share dividend of three cents, or three per cent, to $1.08 per share, payable on and after May 22, 2020, to common shareholders of record at the close of business on April 23, 2020.
The Board of Directors o... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... |
24,688 | 2020-02-19 00:00:00 UTC | Where Will Gilead Sciences Be in 10 Years? | ABBV | https://www.nasdaq.com/articles/where-will-gilead-sciences-be-in-10-years-2020-02-19 | null | null | Biotech investing is generally cyclic in nature. The interplay between innovation and patent expirations makes many of these companies prone to enormous swings in revenue every couple of years. To smooth out the edges, biotechs must continually restock the cupboard through a mix of organic pipeline development and busi... | Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in... | Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and-butter franchise of anti-inflammatory drugs with filgotinib is a questionable investing thesis, to put it mildly. AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in... | So if past is indeed prologue, Gilead seems more likely to continue to flounder and slowly lose even more value over the next 10 years, the inevitable outcome of which seems to be that Johnson & Johnson, Pfizer, or maybe even AbbVie will acquire Gilead in the latter half of the decade. Therefore, the idea that Gilead i... | AbbVie, after all, returned filgotinib's commercial rights to Galapagos back in 2015 to focus on the development of Rinvoq, a drug that has already hit the market and is off to a blazing start. Therefore, the idea that Gilead is suddenly going to turn the corner by attempting to go after AbbVie's (NYSE: ABBV) bread-and... |
24,689 | 2020-02-18 00:00:00 UTC | 17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan | ABBV | https://www.nasdaq.com/articles/17-consumer-groups-and-unions-ask-ftc-to-block-abbvies-acquisition-of-allergan-2020-02-18 | null | null | Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. The organizations, which represent over 10 million subscribers and members, originally raised concerns in September that the merger would harm... | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Al... | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Al... | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to... | Given AbbVie's strong position in the autoimmune diseases space with Humira and Skyrizi, the groups are concerned that divesting rights to brazikumab may not do enough to support a competitive marketplace. Seventeen consumer groups and unions have again voiced their opposition to AbbVie's (NYSE: ABBV) acquisition of Al... |
24,690 | 2020-02-18 00:00:00 UTC | IVV, MDT, ABBV, PYPL: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/ivv-mdt-abbv-pypl%3A-etf-outflow-alert-2020-02-18 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $356.0 million dollar outflow -- that's a 0.2% decrease week over week (from 651,100,000 to 650,050,000). Among t... | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year ... | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year ... | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of IVV, in trading today Medtronic PLC (Symbol: MDT) is down about 4.4%, AbbVie Inc (Symbol: ABBV) is down about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
24,691 | 2020-02-18 00:00:00 UTC | Better Buy: AbbVie vs. Eli Lilly | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-eli-lilly-2020-02-18 | null | null | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. The secret to their success has been their laserlike focus on creating value for shareholders through various business development activities, an aggressive appro... | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. Keeping with this theme, AbbV... | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. And with Allergan in the mix, AbbVie should easily generate high single-digit top-line growth in the years ahead. AbbVie and Lilly, in fact, have been two of the ... | Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. Keeping with this theme, AbbV... | AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. And with Allergan in the mix, AbbVie should easily generate high single-digit top-line growth in the years ahead. Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) ha... |
24,692 | 2020-02-18 00:00:00 UTC | Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares | ABBV | https://www.nasdaq.com/articles/moderna-will-rebound-but-wait-for-a-dip-lower-to-buy-shares-2020-02-18 | null | null | The six-month uptrend in Moderna (NASDAQ:) ended on Feb. 12 when the company priced a secondary offering of its stock at $19. That 15% discount in the stock fills the balance sheet with plenty of additional cash, ensuring the company will have the resources it needs to develop therapeutics and vaccines. Plus, now that ... | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. That 15% discount in the stock fills the balance sheet with plenty of additional cash, ensuring the company will have the resources it needs to develop therapeutics and vaccines. Plus, no... | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. Moderna Developing Coronavirus Vaccine On Jan. 23, Moderna gained the marketâÂÂs attention when the Coalition for Epidemic Preparedness Innovations (CEPI) said that it would finance Mo... | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. Moderna Developing Coronavirus Vaccine On Jan. 23, Moderna gained the marketâÂÂs attention when the Coalition for Epidemic Preparedness Innovations (CEPI) said that it would finance Mo... | Regeneron (NASDAQ:), Gilead Sciences (NASDAQ:), AbbVie (NYSE:), and Inovioà(NASDAQ:) are also working on vaccines and treatments. The six-month uptrend in Moderna (NASDAQ:) ended on Feb. 12 when the company priced a secondary offering of its stock at $19. Source: Shutterstock Moderna shares at $19. |
24,693 | 2020-02-16 00:00:00 UTC | Better Buy: AbbVie vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-gilead-sciences-2020-02-16 | null | null | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. Both stocks trailed the S&P 500 index's performance in 2019 by a wide margin.
However, both AbbVie and Gilead have been big winners in the past. And they both could deliver strong return... | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the ... | AbbVie's shares trade at only nine times expected earnings, while Gilead's shares trade at 10.5 times expected earnings. Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. I think that the combination of solid growth despite the headwinds for Humira with ... | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith ... | Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invita... |
24,694 | 2020-02-16 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 2/16/2020 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-2-16-2020-2020-02-16 | null | null | The following are the top rated Healthcare stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Biotechnology ... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea'... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of June 30, 2016, the Pharmaceutical Distribution segment consists o... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Dymatize brand's portfolio includes an assortment of sports nutrition p... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea'... |
24,695 | 2020-02-15 00:00:00 UTC | 3 High-Yielding U.S. Pharmaceutical Companies to Consider | ABBV | https://www.nasdaq.com/articles/3-high-yielding-u.s.-pharmaceutical-companies-to-consider-2020-02-15 | null | null | The stock market has been bullish for years now, and most companies are richly valued as a result. Meanwhile, dividend yields remain low -- right now, the SPDR S&P 500 ETF (NYSEMKT: SPY) offers just 1.7%.
What's an investor seeking returns to do?
One attractive option is the pharmaceutical sector, where some large-cap ... | AbbVie expects to deliver standalone adjusted diluted earnings of between $9.61 and $9.71 a share in 2020, up 7.5% to 8.7%; this guidance excludes intangible asset amortization expenses and other non-cash charges. Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: G... | Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). What to like about AbbVie AbbVie offers a 5.4% d... | Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. What to like about AbbVie AbbVie offers a 5.4% d... | Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD). Bristol-Myers Squibb trades for slightly less than 9 times projected 2020 earnings estimates, and AbbVie trades for less than 10 times 2020 earnings estimates. What to like about AbbVie AbbVie offers a 5.4% d... |
24,696 | 2020-02-14 00:00:00 UTC | 3 Reasons AbbVie Is a Better Bargain Than You Might Think | ABBV | https://www.nasdaq.com/articles/3-reasons-abbvie-is-a-better-bargain-than-you-might-think-2020-02-14 | null | null | At first glance, the picture for AbbVie (NYSE: ABBV) looks bad. The company's top-selling drug that generated over half of the company's total revenue in the past has lost patent exclusivity in Europe and will do so in the U.S. within the next three years. Last year, while the overall market skyrocketed AbbVie's shares... | However, AbbVie CEO Rick Gonzalez noted in the drugmaker's Q4 conference call last week that the company has held on to around two-thirds of the volume for Humira. For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for th... | Humira protection plan is working AbbVie has known for years that the day would come when Humira would face biosimilar competition. Even though some were initially skeptical of the deal, Allergan brings several drugs to AbbVie's lineup that will lower its reliance on Humira. AbbVie has an ace in the hole While AbbVie's... | For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some in... | AbbVie awaits the closing of its acquisition of Allergan (NYSE: AGN), which should be on track to wrap up later in the first quarter of 2020. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prosp... |
24,697 | 2020-02-14 00:00:00 UTC | Could This Cancer Drug Developer’s Stock Make You Rich? | ABBV | https://www.nasdaq.com/articles/could-this-cancer-drug-developers-stock-make-you-rich-2020-02-14-0 | null | null | Bolstered by new data presented at a key medical conference, Aptose Biosciences's (NASDAQ: APTO) stock bolted skyward in December, more than doubling in price. Savvy investors looking for exposure to the high-risk, high-reward biotech sector need to look no further.
Image source: Getty Images
The company's lead drug, C... | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. Bolstered by new data presented at a key medical conference, Aptose Biosciences's (NASDAQ: AP... | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. In November 2019, the FDA approved the drug called Calquence for the treatment of CLL, follow... | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. Brukinsa, a BTK inhibitor approved for patients with mantle cell lymphoma who had at least on... | Fast forward to spring 2015, when AbbVie (NYSE: ABBV) bought Pharmacyclics for $21 billion, or $261.25 per share. In 2019, Imbruvica generated $4.67 billion in sales for AbbVie and $3.41 billion in sales for Johnson & Johnson. Shortly thereafter, Jazz bought the company for $30.25 per share, or $1.5 billion. |
24,698 | 2020-02-13 00:00:00 UTC | Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation | ABBV | https://www.nasdaq.com/articles/inovios-surge-on-a-coronavirus-vaccine-was-just-speculation-2020-02-13 | null | null | The monster rally in shares of Inovio Pharmaceuticals (NASDAQ:) did not last at all. INO stock traded as high as $5.95 at the end of January, but closed Feb. 12 at $3.34. Investors sought any drug company that would promise a vaccine or treatment for the coronavirus from China. But when the reality that getting a drug ... | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. Valuation and My Takeaway on INO Stock As a drug discovery firm, Inovio does not make money. Q1 Q2 Q3 Q4 Year 2020 E ($0.23) 2019 ($0.30) ($0.30) ($0.25) E ($0.24) (... | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. INO stock traded as high as $5.95 at the end of January, but closed Feb. 12 at $3.34. In effect, Inovio stock rose by more than $300 million in market capitalization... | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. In effect, Inovio stock rose by more than $300 million in market capitalization on news of just $9 million of funding. Valuation and My Takeaway on INO Stock As a dr... | AbbVieâÂÂs (NYSE:) HIV drug Aluvia â a combination of lopinavir and ritonavir â will also be used to treat those infected with the new virus. In effect, Inovio stock rose by more than $300 million in market capitalization on news of just $9 million of funding. Another 453 of the severely infected patients ... |
24,699 | 2020-02-12 00:00:00 UTC | Allergan Pins Hopes on Millennials With Juvederm Marketing | ABBV | https://www.nasdaq.com/articles/allergan-pins-hopes-on-millennials-with-juvederm-marketing-2020-02-12 | null | null | Allergan (NYSE: AGN) is continuing its strategy of targeting millennials with its new advertising campaign. In what could be seen as a counterintuitive strategy, the campaign is the latest one for the company's popular Juvederm dermal filler, a product that older customers traditionally use for cosmetic alterations.
Al... | Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Both Allergan and AbbVie closed slightly higher in tradi... | Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Both Allergan and AbbVie closed slightly higher in tradi... | Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Both Allergan and AbbVie closed slightly higher in tradi... | Allergan and AbbVie are planning to house these goods in a new Allergan Aesthetics business unit. Although Allergan is in the process of merging with pharmaceutical major AbbVie (NYSE: ABBV), it seems that change won't affect the future of its aesthetic products. Both Allergan and AbbVie closed slightly higher in tradi... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.